Open an account

Organon

OGN · NYSE

$13.76+$0.01 (+0.07%)TodayMarket closed ·
Prev close $13.75

About OGN

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Employees
10,000
Headquarters
Jersey City, New Jersey
Listed
May 14, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
organon.com

OGN key statistics

Market cap
3.61B
Price-earnings ratio
17.63
Dividend yield
0.50%
Average volume
2.14M
Volume
2.55M
Open price
$13.75
High today
$13.80
Low today
$13.74
52 Week high
$13.83
52 Week low
$5.69

Organon (OGN) at a glance

As of Oct 20, 2026, Organon (OGN) shares are priced at $13.76, giving the company a market cap of 3.61B, a price-to-earnings ratio of 17.63 and a dividend yield of 0.50%.

Today the stock has traded between $13.74 and $13.80. The current price is 0.1% above the day's low and 0.3% below its high.

Volume so far is 2.55M shares, in line with the average of 2.14M shares a day.

Over the past year Organon has ranged from $5.69 to $13.83, and now sits 99% of the way up that range.

Organon met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.85 per share against an estimate of $0.9273.

The average analyst price target is $11.48, 16.6% below the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 5 analyst ratings say Buy
  • Buy0.0%
  • Hold60.0%
  • Sell40.0%
Price target · 6 analystsAvg $11.48
Low
$8.08
Now
$13.76
High
$14.70

OGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 6.6% on average.

  1. Q3 FY24: reported $0.87 per share against an estimate of $0.9125
  2. Q4 FY24: reported $0.90 per share against an estimate of $0.8752
  3. Q1 FY25: reported $1.02 per share against an estimate of $0.9072
  4. Q2 FY25: reported $1.00 per share against an estimate of $0.9573
  5. Q3 FY25: reported $1.01 per share against an estimate of $0.9457
  6. Q4 FY25: reported $0.63 per share against an estimate of $0.7344
  7. Q1 FY26: reported $0.71 per share against an estimate of $0.8376
  8. Q2 FY26: reported $0.85 per share against an estimate of $0.9273

OGN news

  • Press releaseBusiness Wire

    Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

  • Press releaseBusiness Wire

    Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

  • Press releaseBusiness Wire

    Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

  • Press releaseBusiness Wire

    Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

  • Press releaseBusiness Wire

    Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

  • Press releaseBusiness Wire

    Organon Announces Quarterly Dividend

  • Press releaseBusiness Wire

    New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

  • Press releaseBusiness Wire

    Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Similar companies

Companies in the same industry as Organon

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.